DormaTarg, Inc.

DormaTarg is developing DT330, one of three synthetic anticancer drugs that inhibit recurrence in metastasis prone cancers, like triple negative breast cancer.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Oklahoma City, OK, US
  • Currency USD
  • Founded April 2007
  • Employees 5
  • Website dormatarg.com

Company Summary

DormaTarg, an Oklahoma based pharmaceutical company developing a series of small molecule anti-cancer drugs (DT330) that inhibit recurrence in metastasis prone cancers. We are seeking initial FDA approval as an adjuvant maintenance therapy for patients with triple negative breast cancer (TNBC). We also have plans to repurpose DT330 for other highly metastatic cancers such as surgery eligible pancreatic, bladder and non small cell lung cancers.

Team

  • Kris Vermelis
    Director of Business Development

    Previously worked for Charlesson, LLC and Analytical Research Labs, both Oklahoma based companies, one developing drugs for macular degeneration and glaucoma the other is a GLP contract research facility. Additionally, coordinated and wrote over $40MM in project development grants throughout the research park.

  • Mike Ihnat
    Director of Drug Development

    Dr. Michael Ihnat received his PhD in Pharmacology-toxicology from Dartmouth. After completing a post-doctoral position at Fred Hutchinson Cancer Center/University of Washington, Mike came to the University of Oklahoma, where he soon met with Dr. Hurst because of their common interest in 3-dimensional culture effects on drug sensitivity. He has over 20 years of drug development experience and is a reviewer for the National Cancer SBIR program.

  • Robert Hurst, PhD
    President and Chief Scientific Officer

    Dr. Robert Hurst received his PhD from Florida State University in 1969 in biochemistry and has over 30 years of experience in cancer research with a focus on the emergence of the malignant and invasive/metastatic phenotypes.

Advisors

  • Richard Rainey
    Venture Advisor
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free